An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Jenny Y. Xue(Memorial Sloan Kettering Cancer Center), Piro Lito(Memorial Sloan Kettering Cancer Center), Neelam Chaudhary(Memorial Sloan Kettering Cancer Center), Greg J. Riely(Memorial Sloan Kettering Cancer Center), Fabiola Cechhi, Luciano G. Martelotto(Centre for Cancer Biology), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), Scott W. Lowe(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Bob T. Li(Memorial Sloan Kettering Cancer Center), Kerry Scott, Todd Hembrough(OncoPlex Diagnostics (United States)), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Ulrika Stierner(University of Gothenburg), Neal Rosen(Memorial Sloan Kettering Cancer Center), Jonas A. Nilsson(The University of Western Australia), Jorge S. Reis‐Filho(AstraZeneca (France)), Alberto Vides(Memorial Sloan Kettering Cancer Center), Trang Thi(Memorial Sloan Kettering Cancer Center), Sarit Schwartz(OncoPlex Diagnostics (United States)), Timour Baslan(University of Pennsylvania), Martha Solomon(Memorial Sloan Kettering Cancer Center), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center)
Cited by 181
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k